

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

A. For Equity Issues

1 Type of issue (IPO/FPO)	Initial Public Offering (IPO) on SME Platform	Name of the Issue: <i>Surrest Lifescience Limited</i>
2 Issue size (₹ crore)	₹ 10.85	
3 Grade of issue alongwith name of the rating agency	Not Applicable as the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018.	
4 Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.	44.34	
5 OIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Regulation 31 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015)		
(i) allotment in the issue	NIL	
(ii) at the end of the 1st Quarter immediately after the listing of the issue	NIL	
(iii) at the end of 1st FY	NIL	
(iv) at the end of 2nd FY	NIL	
(v) at the end of 3rd FY	NIL	

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under SEBI (LODR) Regulations, 2015

Parameters	1st FY(2024)	2nd FY(2025)	3rd FY(2026)
Income from operations	Will be updated at the end of 31st March 2024	Will be updated at the end of 31st March 2025	Will be updated at the end of 31st March 2026
Net Profit for the period	Will be updated at the end of 31st March 2024	Will be updated at the end of 31st March 2025	Will be updated at the end of 31st March 2026
Paid-up equity share capital	Will be updated at the end of 31st March 2024	Will be updated at the end of 31st March 2025	Will be updated at the end of 31st March 2026
Reserves excluding revaluation reserves	Will be updated at the end of 31st March 2024	Will be updated at the end of 31st March 2025	Will be updated at the end of 31st March 2026

7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)

(i) at the end of 1st FY	Will be updated at the end of 31st March 2024
(ii) at the end of 2nd FY	Will be updated at the end of 31st March 2025
(iii) at the end of 3rd FY	Will be updated at the end of 31st March 2026

8 Change, if any, in directors of issuer from the disclosures in the offer document (See Regulation 30 of SEBI(LODR) Regulations, 2015)

(i) at the end of 1st FY	Will be updated at the end of 31st March 2024
(ii) at the end of 2nd FY	Will be updated at the end of 31st March 2025
(iii) at the end of 3rd FY	Will be updated at the end of 31st March 2026

9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 32 of SEBI(LODR), Regulations, 2015)

(i) as disclosed in the offer document	NA
(ii) Actual implementation	NA
(iii) Reasons for delay in implementation, if any	NA

10 Status of utilization of issue proceeds (as submitted to stock exchanges under Regulation 32 of SEBI(LODR), Regulations, 2015)

(i) as disclosed in the offer document	No.	Particular	(₹ in lacs)
	1	a.Meeting Working Capital Requirement	855
	b.General Corporate Purposes	140	
	TOTAL	995.00	

(ii) Actual utilization	No.	Particular	(₹ in lacs)
	1	a.Meeting Working Capital Requirement	No information available
	b.General Corporate Purposes	No information available	
	TOTAL	-	

(iii) Reasons for deviation, if any: No information available
Notes:

11 Comments of monitoring agency, if applicable (See Regulation 262 (1) of SEBI (ICDR) Regulations, 2018 read with SEBI(LODR)Regulations, 2015) -> Not Applicable

12 Price- related data

Issue price (₹):	84.00											
Price parameters	At close of listing day(as on November 20, 2023)	At close of 30th calendar day from listing day(December 19, 2023)	At close of 90th calendar day from listing day(February 16, 2024)*	As at the end of 1st FY after the listing of the issue(as on Closing price High (during the FY) Low (during the FY)			As at the end of 2nd FY after the listing of the issue(as Closing High (during the FY) Low (during the FY)			As at the end of 3rd FY after Closing High Low		
Market Price	79.80	81.1	73.50	NA	NA	NA	NA	NA	NA	NA	NA	NA
Index (of the Designated Stock Exchange) NSE Nifty	19,694.00	21,453.10	22,040.70	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sectoral Index (mention the index that has been considered and reasons for considering the same)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

*Date taken as of 16.02.2024(Friday) since the 90th day falls on i.e 17.02.2024(Saturday)

13 Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated) on Standalone Basis

Accounting ratio	Name of company	As disclosed in the offer document (See SCHEDULE VI to SEBI (ICDR) Regulations, 2018)	At the end of 1st FY 2023-24	At the end of 2nd FY24-25	At the end of 3rd FY25-26
EPS	Issuer:		6.81	NA	NA
	Trident Lifeline Limited		5.23	NA	NA
	Vaishal Pharma Limited		6.26	NA	NA
	Chandra Bhaqat Pharma Limited		1.54	NA	NA
P/E	Issuer:		12.23	NA	NA
	Trident Lifeline Limited		34.91	NA	NA
	Vaishal Pharma Limited		21.54	NA	NA
	Chandra Bhaqat Pharma Limited		69.55	NA	NA
RoNW	Issuer:		5.29	NA	NA
	Trident Lifeline Limited		13.18%	NA	NA
	Vaishal Pharma Limited		16.29%	NA	NA
	Chandra Bhaqat Pharma Limited		4.23%	NA	NA
NAV per share based on balance sheet	Issuer:		10.38	NA	NA
	Trident Lifeline Limited		39.66	NA	NA
	Vaishal Pharma Limited		38.43	NA	NA
	Chandra Bhaqat Pharma Limited		36.42	NA	NA

14 Any other material information

NA

Note: (i) Since the shares of the company were listed on November 20, 2023 we are considering March 31, 2024 as the 1st Financial Year.